GlassScriptPhysician profile
Kedna Robert
NPI 1790213148
$3,763.46
in general payments reported to CMS, 2019-2025
29 companies · $950 in 2025
The $950 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $525 · 2022: $755 · 2023: $791 · 2024: $743 · 2025: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,483.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $846.34 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $473.40 | 2021-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $442.52 | 2021-2025 | Jardiance |
| Cvrx, INC. | $383.88 | 2022-2025 | Barostim Neo System |
| Novo Nordisk INC | $250.18 | 2021-2025 | Ozempic |
| Pfizer INC. | $204.71 | 2021-2025 | |
| Medtronic, INC. | $131.90 | 2025 | Symplicity G3 |
| Amgen INC. | $130.45 | 2021-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $125.18 | 2021-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $116.23 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $112.53 | 2022-2025 | Eliquis, Camzyos |
| Esperion Therapeutics, INC. | $77.47 | 2021-2025 | Nexletol |
| Atricure, INC. | $48.89 | 2024-2025 | Synergy Ablation System |
| Irhythm Technologies, INC. | $43.87 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.85 | 2021-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $39.91 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $30.08 | 2024 | Arcalyst |
| Bardy Diagnostics, INC. | $30.00 | 2022 | |
| Arbor Pharmaceuticals, INC. | $29.34 | 2021 | |
| Edwards Lifesciences Corporation | $28.03 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $26.19 | 2025 | Uptravi |
| United Therapeutics Corporation | $25.55 | 2024 | Tyvaso |
| Scpharmaceuticals INC. | $23.96 | 2024 | |
| Abbott Laboratories | $23.65 | 2025 | Aveir |
| Lexicon Pharmaceuticals, INC. | $20.38 | 2023 | Inpefa |
| Inspire Medical Systems, INC. | $18.61 | 2025 | Inspire |
| Ge Healthcare | $18.51 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $12.97 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $7.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kedna Robert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.